Roche Grabs FDA Nod for Hemophilia A Drug, with Warning

Nov 17, 2017

Roche has won FDA approval for its hemophilia A therapy, emicizumab, which will be marketed as Hemlibra.

The once-weekly injection for adults and pediatric patients with hemophilia A who have developed resistance to other treatments will come with a black box warning about the risk of blood clots.

Analysts polled by Reuters predict that Hemlibra will produce about $1.6 billion in annual sales by 2022.

The approval follows months of legal battles with rival Shire, with Shire alleging that Roche released misleading statements about the drug and under-reported adverse events in a Phase 3 trial.

 

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments